Skip to main content
SpringerLink
Log in
Book cover

Metastasis of Breast Cancer pp 279–305Cite as

Prognostic and predictive factors in human breast cancer

  • Chapter

  • 1214 Accesses

Part of the book series: Cancer Metastasis – Biology and Treatment ((CMBT,volume 11))

Abstract

More than 210,000 Americans will be diagnosed with breast cancer each year and more than 41,000 will die from this disease. Over the last two decades many novel therapies have been introduced. However, due to the limited availability and accuracy of prognostic and predictive markers, many patients will have to be treated for the benefit of a few. The lack of precise predictive markers not only pertains to the use of chemotherapy, but also to hormonal or targeted therapy. Still more than half of the patients treated will not derive a benefit. Currently, the prognosis and treatment plan for early stage breast cancer is based on the number of involved lymph nodes, the size of the tumor, the histological grade and type, as well as lymphatic and vascular invasion which will determine the potential benefits from adjuvant chemo-and radiation therapy. Further therapeutic intervention, targeting estrogen receptor and HER2 signaling pathways, are based on the qualitative and quantitative assessment of the estrogen receptor (ER) and progesterone receptor (PR) status and HER2 expression by immunohistochemistry or the HER2 amplification by fluorescence in situ hybridization. The rapid emergence of data on the prognostic and predictive values of gene expression patterns and the better definition of therapeutic targets will lead to significant change in the assessment and treatment of breast cancer in the near future.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Chia SK, Speers CH, Bryce CJ, Hayes MM, Olivotto IA. Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies. J Clin Oncol. 2004; 22(9): 1630-1637

    PubMed  Google Scholar 

  2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics. 2006, CA Cancer J Clin. 2006; 56(2): 106-130

    PubMed  Google Scholar 

  3. Wahl RL, Siegel BA, Coleman RE, Gatsonis CG. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group. J Clin Oncol. 2004; 22(2): 277-285

    PubMed  Google Scholar 

  4. Fisher B, Bauer M, Wickerham DL, Redmond CK, Fisher ER, Cruz AB, Foster R, Gardner B, Lerner H, Margolese R, et al., Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer. 1983; 52(9): 1551-1557

    PubMed  CAS  Google Scholar 

  5. Truong PT, Berthelet E, Lee J, Kader HA, Olivotto IA. The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes. Cancer. 2005; 103(10): 2006-2014

    PubMed  Google Scholar 

  6. Nieweg OE, Jansen L, Valdes Olmos RA, Rutgers EJ, Peterse JL, K. Hoefnagel A, Kroon BB. Lymphatic mapping and sentinel lymph node biopsy in breast cancer. Eur J Nucl Med. 1999; 26(4 Suppl): S11-16

    PubMed  CAS  Google Scholar 

  7. Cox CE, Pendas S, Cox JM, Joseph E, Shons AR, Yeatman T, Ku NN, Lyman GH, Berman C, Haddad F, Reintgen DS. Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. Ann Surg. 1998; 227(5): 645-651; discussion 651-643

    PubMed  CAS  Google Scholar 

  8. de Widt-Levert L, Tjan-Heijnen V, Bult P, Ruers T, Wobbes T. Stage migration in breast cancer: surgical decisions concerning isolated tumour cells and micro- metastases in the sentinel lymph node. Eur J Surg Oncol. 2003; 29(3): 216-220

    PubMed  Google Scholar 

  9. Cox C, White L, Allred N, Meyers M, Dickson D, Dupont E, Cantor A, Ly Q, Dessureault S, King J, Nicosia S, Vrcel V, Di.z N, Survival outcomes in node- negative breast cancer patients evaluated with complete axillary node dissection versus sentinel lymph node biopsy. Ann Surg Oncol. 2006; 13(5): 708-711

    PubMed  Google Scholar 

  10. Varghese P, Mostafa A, Abdel-Rahman AT, Akberali S, Gattuso J, Canizales A, Wells CA, Carpenter R. Methylene blue dye versus combined dye-radioactive tracer technique for sentinel lymph node localisation in early breast cancer. Eur J Surg Oncol. (2006), in press

    Google Scholar 

  11. Wong SL, Edwards MJ, Chao C, Tuttle TM, Noyes RD, Carlson DJ, Cerrito PB, McMasters KM. Sentinel lymph node biopsy for breast cancer: impact of the number of sentinel nodes removed on the false-negative rate. J Am Coll Surg. 2001; 192(6), 684-689; discussion 689-691

    PubMed  CAS  Google Scholar 

  12. Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, Intra M, Veronesi P, Robertson C, Maisonneuve P, Renne G, De Cicco C, De Lucia F, Gennari R. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003; 349(6), 546-553

    PubMed  Google Scholar 

  13. Vanderveen KA, Schneider PD, Khatri V P, Goodnight JE, Bold R J. Upstaging and improved survival of early breast cancer patients after implementation of sentinel node biopsy for axillary staging. Ann Surg Oncol. 2006; 13(11), 1450-1456

    PubMed  Google Scholar 

  14. Amersi F and Hansen NM. The benefits and limitations of sentinel lymph node biopsy. Curr Treat Options Oncol. 2006; 7(2), 141-151

    PubMed  Google Scholar 

  15. Krag DN, Julian TB, Harlow SP, Weaver DL, Ashikaga T, Bryant J, Single RM, Wolmark N. NSABP-32: Phase III, randomized trial comparing axillary resection with sentinal lymph node dissection: a description of the trial. Ann Surg Oncol. 2004; 11(3 Suppl), 208-210

    Google Scholar 

  16. Dabbs DJ, Fung M, Landsittel D, McManus K, Johnson R. Sentinel lymph node micrometastasis as a predictor of axillary tumor burden. Breast J. 2004; 10(2), 101-105.

    PubMed  Google Scholar 

  17. Rosen PP, Saigo PE, Braun DW, Weathers E, Fracchia AA, Kinne DW. Axillary micro- and macrometastases in breast cancer: prognostic significance of tumor size. Ann Surg. 1981; 194(5): 585-591

    Article  PubMed  CAS  Google Scholar 

  18. Shen J, Hunt KK, Mirza NQ, Krishnamurthy S, Singletary SE, Kuerer HM, Meric-Bernstam F, Feig B, Ross MI, Ames FC, Babiera GV. Intramammary lymph node metastases are an independent predictor of poor outcome in patients with breast carcinoma, Cancer. 2004; 101(6): 1330-1337

    PubMed  Google Scholar 

  19. Vinh-Hung V, Verschraegen C, Promish DI, Cserni G, Van de Steene J, Tai P, Vlastos G, Voordeckers M, Storme G, Royce M. Ratios of involved nodes in early breast cancer. Breast Cancer Res. 2004; 6(6): R680-688

    PubMed  Google Scholar 

  20. Voordeckers M, Vinh-Hung V, Van de Steene J, Lamote J, Storme G. The lymph node ratio as prognostic factor in node-positive breast cancer. Radiother Oncol. 2004; 70(3): 225-230

    PubMed  Google Scholar 

  21. Woodward WA, Vinh-Hung V, Ueno NT, Cheng YC, Royce M, Tai P, Vlastos G, Wallace AM, Hortobagyi GN, Nieto Y. Prognostic value of nodal ratios in node-positive breast cancer. J Clin Oncol. 2006; 24(18), 2910-2916

    PubMed  Google Scholar 

  22. Rosen PP, Groshen S, Kinne DW, Norton L. Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J Clin Oncol. 1993; 11(11): 2090-2100

    PubMed  CAS  Google Scholar 

  23. Rosen PP, Groshen S, Kinne DW. Prognosis in T2N0M0 stage I breast carcinoma: a 20-year follow-up study. J Clin Oncol. 1991; 9(9): 1650-1661

    PubMed  CAS  Google Scholar 

  24. Tubiana M and Koscielny S. The natural history of breast cancer: implications for a screening strategy. Int J Radiat Oncol Biol Phys. 1990; 19(5): 1117-1120

    PubMed  CAS  Google Scholar 

  25. Diab SG, Elledge RM, Clark GM. RESPONSE: Re: Tumor Characteristics and Clinical Outcome of Elderly Women With Breast Cancer. J Natl Cancer Inst. 2001; 93(1): 65-66

    PubMed  Google Scholar 

  26. Le Doussal V, Tubiana-Hulin M, Friedman S, Hacene K, Spyratos F, Brunet M. Prognostic value of histologic grade nuclear components of Scarff-Bloom- Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer. 1989; 64(9): 1914-1921

    PubMed  CAS  Google Scholar 

  27. Fisher ER, Redmond C, Fisher B, Bass G. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Projects (NSABP). Prognostic discriminants for 8-year survival for node-negative invasive breast cancer patients. Cancer. 1990; 65(9 Suppl): 2121-2128

    PubMed  CAS  Google Scholar 

  28. Turner RR, Chu KU, Qi K, Botnick LE, Hansen NM, Glass EC, Giuliano AE. Pathologic features associated with nonsentinel lymph node metastases in patients with metastatic breast carcinoma in a sentinel lymph node. Cancer. 2000; 89(3): 574-581

    PubMed  CAS  Google Scholar 

  29. Rosen PP, Groshen S, Saigo PE, Kinne DW, Hellman S. Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. J Clin Oncol. 1989; 7(9): 1239-1251

    PubMed  CAS  Google Scholar 

  30. Van den Eynden GG, Van der Auwera I, Van Laere SJ, Colpaert CG, van Dam P, Dirix LY, Vermeulen PB, Van Marck EA. Distinguishing blood and lymph vessel invasion in breast cancer: a prospective immunohistochemical study. Br J Cancer. 2006; 94(11): 1643-1649

    PubMed  CAS  Google Scholar 

  31. Nixon AJ, Neuberg D, Hayes DF, Gelman R, Connolly JL, Schnitt S, Abner A, Recht A, Vicini F, Harris JR. Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol. 1994; 12(5): 888-894

    PubMed  CAS  Google Scholar 

  32. Albain KS, Allred DC, Clark GM. Breast cancer outcome and predictors of outcome: are there age differentials? J Natl Cancer Inst Monogr. 1994; 16, 35-42

    PubMed  Google Scholar 

  33. Colleoni M, Rotmensz N, Peruzzotti G, Maisonneuve P, Orlando L, Ghisini R, Viale G, Pruneri G, Veronesi P, Luini A, Intra M, Cardillo A, Torrisi R, Rocca A, Goldhirsch A. Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease. Ann Oncol. 2006; 17(10): 1497-1503

    PubMed  CAS  Google Scholar 

  34. Smigal C, Jemal A. Ward E, Cokkinides V, Smith R, Howe HL, Thun M. Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin. 2006; 56(3): 168-183

    PubMed  Google Scholar 

  35. Baldetorp B, Stal O, Ahrens O, Cornelisse C, Corver W, Falkmer U, Ferno M. Different calculation methods for flow cytometric S-phase fraction: prognostic implications in breast cancer? The Swedish Society of Cancer Study Group, Cytometry. 1998; 33(4): 385-393

    CAS  Google Scholar 

  36. Chassevent A, Jourdan ML, Romain S, Descotes F, Colonna M, Martin PM, Bolla M, Spyratos F. S-phase fraction and DNA ploidy in 633 T1T2 breast cancers: a standardized flow cytometric study. Clin Cancer Res. 2001; 7(4): 909-917

    PubMed  CAS  Google Scholar 

  37. Vielh P, Carton M, Padoy E, de Rycke Y, Klijanienko J, El-Naggar AK, Asselain B. S-phase fraction as an independent prognostic factor of long-term overall survival in patients with early-stage or locally advanced invasive breast carcinoma. Cancer. 2005; 105(6): 476-482

    PubMed  Google Scholar 

  38. Silvestrini R, Daidone MG, Valagussa P, Di Fronzo G, Mezzanotte G, Mariani L, Bonadonna G. 3H-thymidine-labeling index as a prognostic indicator in nodepositive breast cancer. J Clin Oncol. 1990; 8(8): 1321-1326

    PubMed  CAS  Google Scholar 

  39. Bilir A, Ozmen V, Kecer M, Eralp Y, Cabioglu N, Ahishali B, Camlica H, Aydiner A. Thymidine labeling index: prognostic role in breast cancer. Am J Clin Oncol. 2004; 27(4): 400-406

    PubMed  Google Scholar 

  40. Baak JP, van Diest PJ, Voorhorst FJ, van der Wall E, Beex LV, Vermorken JB, Janssen EA. Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years. J Clin Oncol. 2005; 23(25): 5993-6001

    PubMed  Google Scholar 

  41. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol. 2005; 23(28): 7212-7220

    PubMed  CAS  Google Scholar 

  42. Haerslev T and Jacobsen GK. Proliferating cell nuclear antigen in breast carcinomas. An immunohistochemical study with correlation to histopathological features and prognostic factors. Virchows Arch. 1994; 424(1): 39-46

    PubMed  CAS  Google Scholar 

  43. Horiguchi J, Iino Y, Takei H, Maemura M, Takeyoshi I, Yokoe T, Ohwada S, Oyama T, Nakajima T, Morishita Y. Long-term prognostic value of PCNA labeling index in primary operable breast cancer. Oncol Rep. 1998; 5(3): 641-644

    PubMed  CAS  Google Scholar 

  44. Foekens JA, Look MP, Bolt-de Vries J, Meijer-van Gelder ME, van Putten WL, Klijn JG. Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients. Br J Cancer. 1999; 79(2): 300-307

    PubMed  CAS  Google Scholar 

  45. Foekens JA, van Putten WL, Portengen H, de Koning HY, Thirion B, Alexieva-Figusch J, Klijn JG. Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis. J Clin Oncol. 1993; 11(5): 899-908

    PubMed  CAS  Google Scholar 

  46. Rodriguez J, Vazquez J., Corte MD, Lamelas M, Bongera M, Corte MG, Alvarez A, Allende M, Gonzalez L, Sanchez M, Vijande M, Garcia Muniz J, Vizoso F. Clinical significance of cathepsin D concentration in tumor cytosol of primary breast cancer. Int J Biol Markers. 2005; 20(2): 103-111

    PubMed  CAS  Google Scholar 

  47. Lorincz T, Toth J, Szendroi M, Timar J. Microvascular density of breast cancer in bone metastasis: influence of therapy. Anticancer Res. 2005; 25(4): 3075-3081

    PubMed  Google Scholar 

  48. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst. 1992; 84(24): 1875-1887

    PubMed  CAS  Google Scholar 

  49. Manders P, Beex LV, Tjan-Heijnen VC, Geurts-Moespot J, Van Tienoven TH, Foekens JA, Sweep CG. The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy. Br J Cancer. 2002; 87(7): 772-778

    PubMed  CAS  Google Scholar 

  50. Nathanson SD, Zarbo RJ, Wachna DL, Spence CA, Andrzejewski TA, Abrams J. Microvessels that predict axillary lymph node metastases in patients with breast cancer, Arch Surg. 2000; 135(5): 586-593; discussion 593-584

    PubMed  CAS  Google Scholar 

  51. Guidi AJ, Berry DA, Broadwater G, Perloff M, Norton L, Barcos MP, Hayes DF. Association of angiogenesis in lymph node metastases with outcome of breast cancer. J Natl Cancer Inst. 2000; 92(6): 486-492

    PubMed  CAS  Google Scholar 

  52. Ludovini V, Sidoni A, Pistola L, Bellezza G, De Angelis V, Gori S, Mosconi AM, Bisagni G, Cherubini R, Bian AR, Rodino C, Sabbatini R, Mazzocchi B, Bucciarelli E, Tonato M, Colozza M. Evaluation of the prognostic role of vascular endothelial growth factor and microvessel density in stages I and II breast cancer patients. Breast Cancer Res Treat. 2003; 81(2): 159-168

    PubMed  CAS  Google Scholar 

  53. Diel IJ, Kaufmann M, Costa SD, Holle R, von Minckwitz G, Solomayer EF, Kaul S, Bastert G. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst. 1996; 88(22): 1652-1658

    PubMed  CAS  Google Scholar 

  54. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, Schlimok G, Diel IJ, Gerber B, Gebauer G, Pierga JY, Marth C, Oruzio D, Wiedswang G, Solomayer EF, Kundt G, Strobl B, Fehm T, Wong GY, Bliss J, Vincent-Salomon A, Pantel K. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 2005; 353(8): 793-802

    PubMed  CAS  Google Scholar 

  55. Grann VR, Troxel AB, Zojwalla NJ, Jacobson JS, Hershman D, Neugut AI. Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer. 2005; 103(11): 2241-2251

    PubMed  CAS  Google Scholar 

  56. Fisher B, Redmond C, Fisher ER, Caplan R. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol. 1988; 6(7): 1076-1087

    PubMed  CAS  Google Scholar 

  57. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365(9472): 1687-1717

    Google Scholar 

  58. Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, Martino S, Perez EA, Muss HB, Norton L, Hudis C, Winer EP. Estrogenreceptor status and outcomes of modern chemotherapy for patients with nodepositive breast cancer. JAMA. 2006; 295(14): 1658-1667

    PubMed  CAS  Google Scholar 

  59. Levine MN, Pritchard KI, Bramwell VH, Shepherd LE, Tu D, Paul N, Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol. 2005; 23(22): 5166-5170

    PubMed  CAS  Google Scholar 

  60. Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, Valero V, Buchholz T, Meric F, Middleton L, Hortobagyi GN, Gonzalez-Angulo AM. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol. 2006; 24(7): 1037-1044

    PubMed  Google Scholar 

  61. Kuukasjarvi T, Kononen J, Helin H, Holli K, Isola J. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol. 1996; 14(9): 2584-2589

    PubMed  CAS  Google Scholar 

  62. Slamon DJ and Clark GM. Amplification of c-erbB-2 and aggressive human breast tumors? Science. 1988; 240(4860): 1795-1798

    PubMed  CAS  Google Scholar 

  63. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science. 1987; 235(4785): 177-182

    PubMed  CAS  Google Scholar 

  64. Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer, J Pathol. 2003; 200(3): 290-297

    PubMed  CAS  Google Scholar 

  65. Andrulis IL, Bull SB, Blackstein ME, Sutherland D, Mak C, Sidlofsky S, Pritzker KP, Hartwick RW, Hanna W, Lickley L, Wilkinson R, Qizilbash A, Ambus U, Lipa M, Weizel H, Katz A, Baida M, Mariz S, Stoik G, Dacamara P, Strongitharm D, Geddie W, McCready D. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group, J Clin Oncol. 1998; 16(4):1340-1349

    CAS  Google Scholar 

  66. Yaziji H, Goldstein LC, Barry TS, Werling R, Hwang H, Ellis GK, Gralow JR, Livingston RB, Gown A M. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA. 2004; 291(16): 1972-1977

    PubMed  CAS  Google Scholar 

  67. Mass RD, Press MF, Anderson S, Cobleigh MA, Vogel CL, Dybdal N, Leiberman G, Slamon DJ. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer. 2005; 6(3): 240-246

    PubMed  Google Scholar 

  68. Love RR, Duc NB, Havighurst TC, Mohsin SK, Zhang Q, DeMets DL, Allred DC. Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. J Clin Oncol. 2003; 21(3): 453-457

    PubMed  CAS  Google Scholar 

  69. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM, Osborne CK. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat. 1992; 24(2): 85-95

    PubMed  CAS  Google Scholar 

  70. Liu Y, el-Ashry D, Chen D, Ding IY, Kern FG. MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifensensitivity in vivo. Breast Cancer Res Treat. 1995; 34(2): 97-117

    PubMed  CAS  Google Scholar 

  71. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman C M, Parker MG, Sliwkowski MX, Slamon D J. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene. 1995; 10(12): 2435-2446

    PubMed  CAS  Google Scholar 

  72. De Laurentiis M, Arpino G, Massarelli E, Ruggiero A, Carlomagno C, Ciardiello F, Tortora G, D’Agostino D, Caputo F, Cancello G, Montagna E, Malorni L, Zinno L, Lauria R, Bianco AR, De Placido S. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res. 2005; 11(13): 4741-4748

    PubMed  CAS  Google Scholar 

  73. Witters LM, Kumar R, Chinchilli VM, Lipton A. Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody. Breast Cancer Res Treat. 1997; 42(1): 1-5

    PubMed  CAS  Google Scholar 

  74. Pritchard KI, Shepherd LE, O’Malley FP, Andrulis IL, Tu D, Bramwell VH, Levine MN. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med. 2006; 354(20): 2103-2111

    PubMed  CAS  Google Scholar 

  75. Jarvinen TA, Tanner M, Rantanen V, Barlund M, Borg A, Grenman S, Isola J, Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol. 2000; 156(3): 839-847

    PubMed  CAS  Google Scholar 

  76. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2- positive operable breast cancer. J Clin Oncol. 2005; 23(16): 3676-3685

    PubMed  CAS  Google Scholar 

  77. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Jr., Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky L. Fehrenbacher TM, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2- positive breast cancer. N Engl J Med. 2005; 353(16): 1673-1684

    PubMed  CAS  Google Scholar 

  78. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353(16): 1659-1672

    PubMed  CAS  Google Scholar 

  79. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344(11): 783-792

    PubMed  CAS  Google Scholar 

  80. Carlson RW, Moench SJ, Hammond ME, Perez EA, Burstein HJ, Allred DC, Vogel CL, Goldstein LJ, Somlo G, Gradishar WJ, Hudis CA, Jahanzeb M, Stark A, Wolff AC, Press MF, Winer EP, Paik S, Ljung BM. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw. 2006; 4 Suppl 3(S1-22; quiz S23-24)

    Google Scholar 

  81. Janicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Hofler H, Graeff H. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat. 1993; 24(3): 195-208

    PubMed  CAS  Google Scholar 

  82. Harbeck N, Kates RE, Schmitt M, Gauger K, Kiechle M, Janicke F, Thomassen C, Look MP, Foekens JA. Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Clin Breast Cancer. 2004; 5(5): 348-352

    PubMed  CAS  Google Scholar 

  83. Janicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, Sweep CG, Selbmann HK, Graeff H, Schmitt M. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst. 2001; 93(12): 913-920

    PubMed  CAS  Google Scholar 

  84. Zemzoum I, Kates RE, Ross JS, Dettmar P, Dutta M, Henrichs C, Yurdseven S, Hofler H, Kiechle M, Schmitt M, Harbeck N. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer. J Clin Oncol. 2003; 21(6): 1022-1028

    PubMed  CAS  Google Scholar 

  85. Meijer-van Gelder ME, Look MP, Peters HA, Schmitt M, Brunner N, Harbeck N, Klijn JG, Foekens JA. Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease. Cancer Res. 2003; 64(13): 4563-4568

    Google Scholar 

  86. Urban P, Vuaroqueaux V, Labuhn M, Delorenzi M, Wirapati P, Wight E, Senn HJ, Benz C, Eppenberger U, Eppenberger-Castori S. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer. J Clin Oncol. 2006; 24(26): 4245-4253

    PubMed  CAS  Google Scholar 

  87. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark NA multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351(27): 2817-2826

    PubMed  CAS  Google Scholar 

  88. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE, Jr, Wickerham DL, Wolmark N. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006; 24(23): 3726-3734

    PubMed  CAS  Google Scholar 

  89. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB, van't Veer LJ, Perou CM. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med. 2006; 355(6): 560-569

    PubMed  CAS  Google Scholar 

  90. Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol. 2005; 23(29): 7350-7360

    PubMed  CAS  Google Scholar 

  91. Sorlie T. Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer. 2004; 40(18): 2667-2675

    PubMed  CAS  Google Scholar 

  92. van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards RA gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002; 347(25): 1999-2009

    PubMed  CAS  Google Scholar 

  93. van’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002; 415(6871): 530-536

    Google Scholar 

  94. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D, Foekens JA. Gene-expression profiles to predict distant metastasis of lymph- node-negative primary breast cancer. Lancet. 2005; 365(9460): 671-679

    PubMed  CAS  Google Scholar 

  95. Foekens JA, Atkins D, Zhang Y, Sweep FC, Harbeck N, Paradiso A, Cufer T, Sieuwerts AM, Talantov D, Span PN, Tjan-Heijnen VC, Zito AF, Specht K, Hoefler H, Golouh R, Schittulli F, Schmitt M, Beex LV, Klijn JG, Wang Y. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer, J Clin Oncol. 2006; 24(11): 1665-1671

    PubMed  CAS  Google Scholar 

  96. Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, Miller MC, Matera J, Repollet M, Doyle GV, Terstappen LW, Hayes DF. Circulating Tumor Cells versus Imaging--Predicting Overall Survival in Metastatic Breast Cancer. Clin Cancer Res. 2006; 12(21): 6403-6409

    PubMed  CAS  Google Scholar 

  97. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8): 781-791

    PubMed  CAS  Google Scholar 

  98. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, Doyle GV, Matera J, Allard WJ, Miller MC, Fritsche HA, Hortobagyi GN, Terstappen LW. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol. 2005; 23(7): 1420-1430

    PubMed  Google Scholar 

  99. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, Matera J, Allard WJ, Doyle GV, Terstappen LW. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progressionfree and overall survival. Clin Cancer Res. 2006; 12(14 Pt 1): 4218-4224

    PubMed  CAS  Google Scholar 

  100. Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, Osborne C K, McGuire W L. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst. 1993; 85(3): 200-206

    PubMed  CAS  Google Scholar 

  101. Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med. 1995; 1(10): 1029-1034

    PubMed  CAS  Google Scholar 

  102. Zellars RC, Hilsenbeck SG, Clark GM, Allred DC, Herman TS, Chamness GC, Elledge RM. Prognostic value of p53 for local failure in mastectomy-treated breast cancer patients. J Clin Oncol. 2000; 18(9): 1906-1913

    PubMed  CAS  Google Scholar 

  103. Malamou-Mitsi V, Gogas H, Dafni U, Bourli A, Fillipidis T, Sotiropoulou M, Vlachodimitropoulos D, Papadopoulos S, Tzaida O, Kafiri G, Kyriakou V, Markaki S, Papaspyrou I, Karagianni E, Pavlakis K, Toliou T, Scopa C, Papakostas P, Bafaloukos D, Christodoulou C, Fountzilas G. Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. Ann Oncol. 2006; 17(10): 1504-1511

    PubMed  CAS  Google Scholar 

  104. Granato AM, Frassineti GL, Giovannini N, Ballardini M, Nanni O, Maltoni R, Amadori D, Volpi A. Do serum angiogenic growth factors provide additional information to that of conventional markers in monitoring the course of metastatic breast cancer? Tumour Biol. 2006; 27(6): 302-308

    PubMed  CAS  Google Scholar 

  105. Alba E, Llombart A, Ribelles N, Ramos M, Fernandez R, Mayordomo JI, Tusquets I, Gil M, Barnadas A, Carabante F, Ruiz M, Vera R, Palomero I, Soriano V, Gonzalez J, Colomer R. Serum endostatin and bFGF as predictive factors in advanced breast cancer patients treated with letrozole. Clin Transl Oncol. 2006; 8(3): 193-199

    PubMed  CAS  Google Scholar 

  106. Cummings J, Smyth JF. DNA topoisomerase I and II as targets for rational design of new anticancer drugs. Ann Oncol. 1993; 4(7): 533-543

    PubMed  CAS  Google Scholar 

  107. Jarvinen TA, Tanner M, Barlund M, Borg A, Isola J. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer. 1999; 26(2): 142-150

    PubMed  CAS  Google Scholar 

  108. Di Leo A, Larsimont D, Gancberg D, Jarvinen T, Beauduin M, Vindevoghel A, Michel J, Focan CH, Ries F, Gobert PH, Closon-Dejardin MT, Dolci S, Rouas G, Paesmans M, Lobelle JP, Isola J, Piccart MJ. HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann Oncol. 2001; 12(8): 1081-1089

    PubMed  CAS  Google Scholar 

  109. Di Leo A, Gancberg D, Larsimont D, Tanner M, Jarvinen T, Rouas G, Dolci S, Leroy JY, Paesmans M, Isola J, Piccart MJ. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res. 2002; 8(5): 1107-1116

    PubMed  CAS  Google Scholar 

  110. Coon JS, Marcus E, Gupta-Burt S, Seelig S, Jacobson K, Chen S, Renta V, Fronda G, Preisler HD. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res. 2002; 8(4): 1061-1067

    PubMed  CAS  Google Scholar 

  111. Park K, Kim J, Lim S, Han S. Topoisomerase II-alpha (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy. Eur J Cancer. 2003; 39(5): 631-634

    PubMed  CAS  Google Scholar 

  112. Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, Nielsen KV, Schonau A, Gunnarsdottir K, Olsen KE, Mouridsen H, Ejlertsen B. retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, metho- trexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol. 2005; 23(30): 7483-7490

    PubMed  CAS  Google Scholar 

  113. Tanner M. Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmstrom P, Wilking N, Nilsson J, Bergh J. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracyclinebased adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol. 2006; 24(16): 2428-2436

    PubMed  CAS  Google Scholar 

  114. Slamon DJ, Eiermann W, Robert N, Pienkowski T, Martin M, Press MF, Bernstein L, Sauter G, Zhou JY, Pawlicki M, Chan M, Smylie M, Liu M, Falkson C, Pinter T, Fornnander T, Shiftan T, Valero V, machey J, Tabah-Fisch I, Buyse M, Lindsay MA, Riva A, Bee V, Pegram M, Press MF, Crown J. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. San Antonio Breast Cancer Symposium. 2005; A1 (abstract)

    Google Scholar 

  115. Press MF, Bernstein L, Sauter G, Zhou JY, Eiermann W, Pienkowski T, Crown J, Robert N, Bee V, Taupin H, Villalobos I, Seelig S, Pegram M, Slamon DJ. Topoisomerase II-alpha gene amplification as a predictor of responsiveness to anthracycline-containing chemotherapy in the Cancer International Research Group 006 clinical trial of trastuzumab (herceptin) in the adjuvant setting. San Antonio Breast Cancer Symposium. 2005; A 1045 (abstract)

    Google Scholar 

  116. Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer. 1996; 77(11): 2318-2324

    PubMed  CAS  Google Scholar 

  117. Lee JS, Wacholder S, Struewing JP, McAdams M, Pee D, Brody LC, Tucker MA, Hartge P. Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 1999; 91(3): 259-263

    PubMed  CAS  Google Scholar 

  118. Haffty BG, Harrold E, Khan AJ, Pathare P, Smith TE, Turner BC, Glazer PM, Ward B, Carter D, Matloff E, Bale AE, Alvarez-Franco M. Outcome of conser- vatively managed early-onset breast cancer by BRCA1/2 status. Lancet. 2002; 359(9316): 1471-1477

    PubMed  Google Scholar 

  119. Hartmann LC, Schaid DJ, Woods JE, Crotty TP, Myers JL, Arnold PG, Petty PM, Sellers TA, Johnson JL, McDonnell SK, Frost MH, Jenkins RB. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 1999; 340(2): 77-84

    PubMed  CAS  Google Scholar 

  120. Domchek SM, Friebel TM, Neuhausen SL, Wagner T, Evans G, Isaacs C, Garber JE, Daly MB, Eeles R, Matloff E, Tomlinson GE, Van’t Veer L, Lynch HT, Olopade OI, Weber BL, Rebbeck TR. Mortality after bilateral salpingooophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol. 2006; 7(3): 223-229

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Experimental Therapeutics and Breast Medical Oncology, Department of Interd, H. Lee Moffitt Cancer Center, 12902 Magnolia Dr, Tampa, 33612, FL, USA

    Soe Maunglay MD

  2. Experimental Therapeutics and Breast Medical Oncology, Department of Interd, H. Lee Moffitt Cancer Center, 12902 Magnolia Dr, Tampa, 33612, FL, USA

    Douglas C. Marchion PhD

  3. Division of Breast Oncology and Experimental Therapeutics, H. Lee Moffitt Cancer Center, 12902 Magnolia Dr, Tampa, 33612, FL, USA

    Pamela N. Münster MD

Authors
  1. Soe Maunglay MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Douglas C. Marchion PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pamela N. Münster MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Surgery, Cardiff University School of Medicine, Heath Park, CF14 4XN, Cardiff, UK

    Robert E. Mansel MS, FRCS, CBE

  2. Michell Cancer Institute, University of South Alabama, 307 N. University Blvd., 2015, 36688, AL, USA

    Oystein Fodstad PhD

  3. Metastasis and Angiogenesis Research Group, Cardiff University School of Medicine, CF14 4XN, Heath Park, Cardiff, UK

    Wen G. Jiang MB, BCh, MD

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer

About this chapter

Cite this chapter

Maunglay, S., Marchion, D.C., Münster, P.N. (2007). Prognostic and predictive factors in human breast cancer. In: Mansel, R.E., Fodstad, O., Jiang, W.G. (eds) Metastasis of Breast Cancer. Cancer Metastasis – Biology and Treatment, vol 11. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-5867-7_14

Download citation

Publish with us

Policies and ethics

Search

Navigation